The INNOVATE Act (H.R.4777) rewrites large parts of section 9 of the Small Business Act to accelerate transition of SBIR/STTR projects into production while hardening award screening for foreign risk. The bill creates a new "strategic breakthrough" funding carve‑out that lets large SBIR agencies award up to $30 million for Phase II projects that show production readiness, establishes a new Phase 1A entry point (small, short awards for first‑time applicants), and tightens direct‑to‑Phase II and Phase III pathways to reduce friction between R&D and acquisition.
At the same time the bill expands research‑security authorities: it defines “foreign risk,” requires strengthened due diligence tied to multiple federal entity lists, broadens agency recovery authority over IP and proceeds, and adds reporting and GAO oversight. It also mandates outreach to rural communities, data tagging changes, limits on proposal submissions, and a prohibition on awarding to applicants with certain disclosed agreements with named third‑party content‑rating or “fact‑checking” organizations.
At a Glance
What It Does
Creates a strategic breakthrough allocation (≈0.25% of an agency’s extramural R&D) that allows agencies with SBIR budgets >$100M to make Phase II awards up to $30M (48‑month max) with 100% non‑federal matching; authorizes 1A pilot awards (1.5–3% of SBIR budgets, up to $40,000) for new entrants; and requires fixed‑price SBIR/STTR contracts unless waived in writing. It adds layered foreign‑risk screening, recovery rules for IP transfers, and reporting requirements.
Who It Affects
Federal SBIR/STTR program offices and program managers, small businesses (especially first‑time applicants and defense/dual‑use vendors), agency acquisition and requirements offices, investors (SBICs/private VCs), and compliance and legal teams responsible for security screening and award administration.
Why It Matters
Shifts SBIR/STTR from pure early‑stage R&D grants toward production‑enabled awards and faster agency buy‑in, while embedding explicit national‑security screening. Companies, investors, and program offices will face different eligibility gates, matching requirements, and monitoring obligations that change commercialization timelines and deal‑making calculus.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill reorganizes SBIR/STTR authority around faster transition and security screening. It creates a “strategic breakthrough allocation” for agencies with large SBIR budgets: agencies must set aside a small percentage of SBIR funds (defined relative to extramural R&D) to back Phase II projects that are production‑oriented.
Those awards can reach $30 million per award (including affiliates/spinouts) for up to 48 months, but recipients must show prior Phase II experience and at least 100% non‑federal matching capital. Agencies must streamline proposal processes, set a 90‑day deadline to complete awards after proposal receipt, and connect awardees directly to program/requirements offices to enable Phase III buys.
To broaden participation, the bill adds a Phase 1A pathway that dedicates 1.5–3% of an agency’s SBIR pool to small, accessible awards (up to $40,000) for firms that have never received SBIR/STTR funding. Phase 1A proposals are short (five pages) and designed to reduce barriers for new entrants; awardees may later pursue Phase I or Phase II.
The bill also caps total Phase I/II award amounts per small business at $75 million, subject to a narrow, non‑delegable national‑security waiver held by the agency SBIR director or Undersecretary.On the security side the INNOVATE Act defines “foreign risk” broadly (foreign affiliations, licensing, joint ventures, investments, research co‑authorship, and contractual ties) and requires agencies to integrate due diligence into award decisions. It cross‑references multiple federal lists (e.g., Entity List, Military End User, UFLPA lists) for risk signals, forbids pre‑award disclosures to applicants that denials were based on foreign risk, and strengthens agency recovery authority — including multi‑year restrictions on selling or licensing IP developed with SBIR/STTR funds to foreign entities of concern.
The bill also requires improved data tagging in the federal procurement and SBIR databases so Phase 1A, direct‑to‑Phase II, strategic breakthrough, and Phase III awards can be tracked.
The Five Things You Need to Know
Strategic Breakthrough Allocation: agencies with SBIR budgets over $100M must fund a strategic breakthrough pool equal to at least 0.25% of their extramural R&D; awards from that pool may reach $30 million per small business (including affiliates) for up to 48 months.
Phase 1A for new entrants: agencies must allocate 1.5–3% of SBIR funds to Phase 1A awards (one per firm max) worth up to $40,000, with five‑page proposals and a 90‑day notification deadline.
Direct‑to‑Phase II caps: agencies may use direct‑to‑Phase II authority but are limited to 10% of their SBIR allocation in a fiscal year (NIH and DoD components allowed up to 30%).
Security and foreign‑risk screening: the bill defines “foreign risk,” requires agencies to run enhanced due diligence tied to federal entity lists, and bars agencies from notifying applicants prior to formal award notices that denial was due to foreign risk.
Censorship‑vendor prohibition and disclosure: applicants must disclose and are barred from awards if they have pending agreements with named entities (NewsGuard, Global Disinformation Index, Internews) or entities whose function is to demonetize or rate domestic outlets based on 'fact‑checking'.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Raise STTR share, SBIR set‑aside minimums
This provision tweaks statutory percentage floor and allocation numbers across SBIR/STTR. It increases certain STTR/related numeric thresholds and inserts a new minimum SBIR participation percentage (3.45% in 2026 and thereafter) and a small STTR minimum (0.20%). Practically, agencies must adjust budgetary set‑asides and reporting to reflect the new statutory floors.
Strategic Breakthrough awards—big Phase II grants tied to production
Creates a narrowly defined strategic breakthrough allocation for participating agencies: the allocation equals at least 0.25% of the agency’s extramural R&D budget. Awards from this pool may reach $30 million per small business (including affiliated entities) and are limited to 48 months. Eligibility requires a prior Phase II award, 100% non‑federal matching funds, market validation, and a program office commitment (program executive officer or higher) that the item meets acquisition/program needs. Agencies must complete awards within 90 days of proposal receipt and implement streamlined submission/contracting processes and direct links to requirements offices to accelerate Phase III transition.
Firm fixed‑price contracts as default
The bill makes firm fixed‑price contracts (per FAR 16.202) the default contracting vehicle for SBIR and STTR funding agreements unless the agency head documents a written determination to use another contract type. This shifts risk allocation toward contractors and standardizes pricing expectations across SBIR/STTR contract awards.
Phase 1A, new‑entrant limits, rural outreach, and anti‑discrimination edits
Establishes Phase 1A as a new pathway for applicants who have never received SBIR/STTR awards, limits Phase 1A proposals to five pages and grants to $40K, and requires agencies to allocate 1.5–3% of SBIR funds to this track. It caps cumulative Phase I/II funding per small business at $75M (waivable only by a senior SBIR official for national security), sets an annual receipts cap for Phase I applicants ($40M), restricts concurrent PI submissions within a single solicitation, and requires agencies and SBA to enhance outreach to rural counties. The bill also rewrites certain ‘‘disadvantaged’’ language to emphasize rural participation and explicitly bars the use of race/gender/ethnicity in award selection or supplemental funding.
Research security: foreign‑risk definition, due diligence, recovery authority, and GAO oversight
Adds a statutory definition of “foreign risk” that covers affiliations, funding, contracts, co‑authorships, and other ties; directs agencies to integrate due diligence checks into award decisions (including checking multiple executive branch lists); prohibits agencies from informing applicants pre‑award that denial was for foreign risk; extends agency recovery authority and places multi‑year (5–10 year) restrictions on sale/licensing of IP developed with SBIR/STTR funds to foreign entities of concern; and tasks GAO with periodic studies on implementation and program effectiveness.
Direct‑to‑Phase II limits and data tagging
Permits direct‑to‑Phase II awards if the agency determines Phase I‑equivalent determinations were met, but caps such awards at 10% of SBIR allocation (30% for NIH and DoD components). It adds new data fields to the SBIR database and FedProc systems so awards can be tagged as Phase 1A, direct‑to‑Phase II, strategic breakthrough, Phase III prime, or Phase III subcontract, enabling better tracking of commercialization outcomes.
Technical fixes, repeals, and authorization extension
Contains technical cleanups (terminology, committee names), repeals of obsolete subsections, and extends the statutory authorization of SBIR/STTR provisions to 2028. Also tightens limits on submissions per solicitation and per year to reduce administrative burdens.
This bill is one of many.
Codify tracks hundreds of bills on Technology across all five countries.
Explore Technology in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- First‑time small business applicants: Phase 1A lowers the entry barrier (short application, small award) and forces agencies to direct outreach to rural communities, widening geographic and institutional access to federal R&D funding.
- Small businesses with production‑ready tech (especially defense/dual‑use vendors): the strategic breakthrough pool and the stronger Phase III connections give capital‑intensive firms a route from prototype to production and a clearer handoff to acquisition offices.
- Agency program and requirements offices: statutory nudges to create direct access mechanisms and faster award timelines simplify procurement of new technologies and provide a pipeline for modernization.
- Domestic investors and SBICs: the bill explicitly directs SBA to connect awardees to SBICs and other private investors, creating more opportunities for follow‑on capital for commercialization.
- Compliance and security teams within agencies: new due diligent frameworks and reporting requirements consolidate security processes and create a single statutory framework for assessing foreign risk.
Who Bears the Cost
- Participating agencies (program and contracting offices): must build streamlined contracting mechanisms, meet 90‑day award deadlines for strategic proposals, implement expanded due diligence, and update data systems—work that will require staff time and possibly new resources.
- Small businesses seeking strategic breakthrough awards: must have prior Phase II experience and present 100% non‑federal matching funds, which privileges better‑capitalized firms and increases fundraising pressure before receiving large awards.
- Awardees with foreign ties or collaborators: enhanced screening, extended post‑award IP restrictions, and the risk of revocation/recovery will deter or complicate collaborations, joint ventures, and cross‑border licensing.
- Investors and venture funds: informational‑rights best practices and the new recovery/IP restrictions increase legal and compliance complexity around term sheets, minority‑investor rights, and exits.
- Third‑party vendors named in the bill (e.g., certain fact‑checking or content‑rating firms): organizations listed in the disclosure/prohibition provisions face contract‑loss exposure and reputational scrutiny.
Key Issues
The Core Tension
The bill's central dilemma is straightforward: accelerate transition from lab to field (large, production‑oriented awards and faster contracting) while preventing adversarial access to U.S. innovation (broad foreign‑risk screening and post‑award IP controls). Measures that speed commercialization—bigger awards, looser contract pathways, streamlined timelines—also increase exposure to foreign exploitation and complicate investor exits; conversely, strict security gates and long‑term transfer limits protect national security but can freeze capital flows and slow the very commercialization the bill aims to promote.
The INNOVATE Act bundles two competing priorities—speeding commercialization and strengthening national security—into one statutory package, and that creates friction. Operationalizing the strategic breakthrough program raises verification problems (how to confirm 100% non‑federal match, measure production readiness, or police aggregate award limits across affiliates).
Agencies face a tight 90‑day window to complete awards, but cohorting technical review, acquisition sign‑offs, and contracting under that timeline will require new interoffice workflows that are not funded in statute.
Security provisions sweep broadly: the statutory “foreign risk” definition covers a wide set of relationships (co‑authorship, investments, licensing), and the bill ties risk signals to many executive‑branch lists that change over time. That raises both transparency and due‑process questions: applicants can be denied or have awards recovered based on cross‑referenced lists or classified sources, and the statute expressly forbids prior informal notice to applicants about foreign‑risk denials.
The IP recovery and transfer restrictions (5‑ and 10‑year horizons) protect security but will chill investors who need clear exit pathways and can complicate mergers, cross‑licensing, or foreign partnerships.
Finally, the censorship‑vendor disclosure/prohibition is operationally blunt. It names specific entities (NewsGuard, Global Disinformation Index, Internews) and sweeps in any vendor whose function is described as demonetizing or rating domestic outlets.
That creates uncertainty for applicants who use common content‑monitoring or analytics services and invites disputes over definitions and scope. Implementation will require extensive rulemaking, interagency coordination, and likely litigation or policy clarification on how disclosures will be interpreted and enforced.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.